Keywords: biocryst, agrees, spa, pivotal, oral, fodosine, trial

BioCryst agrees SPA for pivotal oral Fodosine trial

Article | 16 July 2007

Print This

Alabama, USA-based BioCryst Pharmaceuticals says that it has reached an agreement with the Food and Drug Administration under its Special ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in